GPT and hypertensive disorder: Some selpercatinib‐associated serious AEs leading to dose reduction or treatment interruption have also been reported; hypertension, elevated ALT or AST, and severe gastrointestinal toxicities characterized by small bowel edema and lymphocytic duodenitis [3].